Keyword: Horizon Discovery
Abcam has ended its pursuit of Horizon Discovery one week after going public about its attempt to buy the gene editing specialist.
Horizon issued a strongly worded rebuttal of the offer, calling it “highly opportunistic” and repudiating the strategic rationale for the merger.
Oxford Genetics has licensed CRISPR gene editing technology from ERS Genomics.
Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell.
Desktop Genetics, Horizon Discovery and Vectalys have teamed up to develop custom-made CRISPR lenti-gRNA libraries.
Just a few months after launching with a $55 million Series A round, Third Rock upstart Fulcrum Therapeutics has signed its first major partnership with the U.K.’s Horizon Discovery as they look to put CRISPR to use for rare, genetic diseases.